Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the latest C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback